Download 164.87 Kb.
Note: As per the Zacks Digest model, on proforma basis, COGS is expected to increase 14.8% y/y in FY16 and 5.1% in FY17; while R&D expenses are likely to rise 13.8% y/y in FY16 and decline 9.2% in FY17. Alongside, revenues are likely to increase 15.7% in FY16 and 14.7% in FY17.
Please refer to the Zacks Research Digest spreadsheet on CPHD for more extensive Margins figures.
Earnings per Share
Cepheid’s 1Q16 reported net loss (including one-time items) was $0.09 per share, compared to net income of $0.01 in 1Q15.
Meanwhile, the company delivered adjusted loss (considering stock-based compensation expense as a regular spending) per share of $0.04 in 1Q16, compared to adjusted income per share of $0.06 in 1Q15.
The Zacks Digest loss per share in 1Q16 was in line with the company’s report.
Provided below is a summary of EPS as compiled by the Zacks Digest:
Outlook: For FY16, Cepheid reiterated its adjusted loss per share at the range of $0.29–$0.35 and reported loss per share at the range of $0.51–$0.57.
Please refer to the Zacks Research Digest spreadsheet on CPHD for more extensive EPS figures.
© Copyright 2016, Zacks Investment Research. All Rights Reserved